Product Description
Oseltamivir is a prodrug of oseltamivir carboxylate (Ro 64-0802, GS4071), a potent and selective inhibitor of the neuraminidase glycoprotein essential for replication of influenza A and B viruses. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/11270942/)
Mechanisms of Action: NEU Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Hoffmann-La Roche
Company Location: BASEL SWITZERLAND V8
Company CEO: Severin Schwan
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Belgium, Canada, China, Colombia, Croatia, Germany, Ghana, Hungary, India, Indonesia, Ireland, Japan, Nepal, Netherlands, New Zealand, Pakistan, Portugal, Romania, Saudi Arabia, South Africa, Spain, United Kingdom, United States, Vietnam
Active Clinical Trial Count: 17
Highest Development Phases
Phase 3: COVID-19|Influenza, Human|Pneumonia|Severe Acute Respiratory Syndrome
Phase 1: Acute Respiratory Distress Syndrome|Healthy Volunteers|Kidney Diseases|Kidney Failure, Chronic|Respiratory Insufficiency
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| RECOVERY | P3 |
Recruiting |
Severe Acute Respiratory Syndrome|COVID-19 |
2026-06-30 |
|
| REMAP-CAP | P3 |
Recruiting |
COVID-19|Pneumonia|Influenza, Human |
2026-02-01 |
|
| ZX-7101A-208 | P1 |
Recruiting |
Healthy Volunteers |
2024-04-29 |
|
| CTR20230077 | P1 |
Completed |
Influenza, Human |
2023-09-11 |